Sign In
Buy NVO
$47.08
-4.54 (-8.79%)
At Close: Jul 31, 2026
Obesity battle heats up again as Novo claws way back into race with Lilly
01:02am, Monday, 03'rd Aug 2026
Novo Nordisk investors have found little cause for optimism during a bruising two-year period of profit warnings, leadership upheaval and a sliding share price as rival Eli Lilly streaked ahead. No
Novo Nordisk Shares Plunge After a Key Trial Fails. Should Investors Buy the Dip?
04:55pm, Friday, 31'st Jul 2026
Shares of Danish drugmaker Novo Nordisk fell nearly 10% today. The drop came after an experimental cardiovascular drug failed a late-stage clinical trial.
Novo Nordisk vs Eli Lilly: The Better Buy Before Earnings
01:30pm, Friday, 31'st Jul 2026
Novo Nordisk (NYSE: NVO | NVO Price Prediction) and Eli Lilly (NYSE: LLY) both posted Q1 FY2026 results this spring, and the gap between them keeps widening.
Eli Lilly Stock Has Skyrocketed. Novo Nordisk Has Crashed.
01:30pm, Friday, 31'st Jul 2026
Both companies are giants in diabetes and obesity treatments. Lately, Eli Lilly has moved ahead in the obesity segment.
Why Is BioAge Labs Stock Sinking Friday?
01:24pm, Friday, 31'st Jul 2026
BioAge Labs Inc. (NASDAQ:BIOA) stock plunged Friday after disappointing Phase 3 cardiovascular trial results from Novo Nordisk A/S (NYSE:NVO) sparked concerns about the potential of NLRP3-targeting th
Weight Loss Drug Stocks Novo Nordisk, Eli Lilly Slump Below Key Levels
11:51am, Friday, 31'st Jul 2026
Wegovy and Zepbound makers Novo Nordisk and Eli Lilly faced selling pressure on Friday.
Novo Nordisk Wipes Out $30 Billion In Market Value After Failed Heart Drug Trial
11:15am, Friday, 31'st Jul 2026
$30.7 billion. That's how much was cut from Novo Nordisk's market capitalization as of Friday's share price, lowering from $229.2 billion to $198.5 billion, marking a nearly 69% decline since hitting
Novo Nordisk Stock Drops as Heart Drug Fails Late-Stage Trial
10:56am, Friday, 31'st Jul 2026
The Danish drugmaker is striving to diversify beyond its popular weight-loss drugs, but its anti-inflammatory drug candidate faces a challenge.
Novo Nordisk's stock slumps after failed trial — adding to the company's woes
09:54am, Friday, 31'st Jul 2026
The Danish healthcare company's stock slumped on Friday after it announced the Phase 3 trial failure.
Novo Nordisk Says Anti-Inflammatory Drug Trial Fails to Cut Cardiovascular Risk in High Risk Patients
09:32am, Friday, 31'st Jul 2026
Novo Nordisk A/S (NYSE:NVO) stock plunged on Friday after the company announced disappointing headline results from its ZEUS Phase 3 cardiovascular outcomes trial.
Novo Nordisk Stock Sinks on Disappointing Heart Drug Trial Results
09:17am, Friday, 31'st Jul 2026
U.S.-listed shares of Novo Nordisk closed Thursday up just 1% this year. They look likely to drop into the red today.
Novo Nordisk Stock Tumbles on Late-Stage Trial Results
08:31am, Friday, 31'st Jul 2026
Novo Nordisk A/S (NYSE:NVO) is pointed sharply lower before the open after the drugmaker said its Phase 3 trial of ziltivekimab failed to significantly reduce major adverse cardiovascular events com
Novo Nordisk Shares Drop After Drug Candidate Fails in Cardiovascular Trial
08:02am, Friday, 31'st Jul 2026
Stock was down 9.5% after the company's experimental medicine ziltivekimab didn't achieve the expected risk reduction for major cardiovascular events.
Novo Nordisk shares dive 9% after heart medicine fails trial
07:43am, Friday, 31'st Jul 2026
Novo Nordisk shares dive 9% after heart medicine fails trial
Novo Nordisk's inflammation drug fails to reduce cardiovascular risk in trial
07:34am, Friday, 31'st Jul 2026
Novo Nordisk said on Friday its experimental drug failed to reduce the risk of major cardiovascular events in a late-stage trial involving patients with cardiova
